Publications by authors named "Jenaro A Espitia-Corredor"
Resolvin E1 attenuates doxorubicin-induced cardiac fibroblast senescence: A key role for IL-1β.
Jenaro A Espitia-Corredor Licia Shamoon Francisco Olivares-Silva Constanza Rimassa-Taré Claudia Muñoz-Rodríguez
Biochim Biophys Acta Mol Basis Dis
November 2022
Article Synopsis
- Cardiac fibroblasts (CFs) can become senescent due to stress, contributing to poor outcomes in heart disease, particularly from cardiotoxic drugs like doxorubicin (Doxo), which also triggers inflammation through IL-1β.
- Research shows that Doxo leads to CFs senescence as indicated by increased markers of aging and changes in their secretions, but this process can be countered by Resolvin E1 (RvE1), which has anti-inflammatory properties.
- The study also suggests that the NLRP3 inflammasome and IL-1 receptor pathways are involved in Doxo-induced senescence, and by inhibiting these pathways or using RvE1, the negative effects of Doxo on CF
Angiotensin II Triggers NLRP3 Inflammasome Activation by a Ca Signaling-Dependent Pathway in Rat Cardiac Fibroblast Ang-II by a Ca-Dependent Mechanism Triggers NLRP3 Inflammasome in CF.
Jenaro Antonio Espitia-Corredor Pía Boza Claudio Espinoza-Pérez José Miguel Lillo Constanza Rimassa-Taré
Inflammation
December 2022
Angiotensin II (Ang-II) is a widely studied hypertensive, profibrotic, and pro-inflammatory peptide. In the heart, cardiac fibroblasts (CF) express type 1 angiotensin II receptors (AT1R), Toll-like receptor-4 (TLR4), and the NLRP3 inflammasome complex, which play important roles in pro-inflammatory processes. When activated, the NLRP3 inflammasome triggers proteolytic cleavage of pro-IL-1, resulting in its activation.
View Article and Find Full Text PDFArticle Synopsis
- Endothelial cell senescence leads to chronic inflammation and cardiovascular issues, and can be triggered by various stressors, including cancer drugs like Doxorubicin (Doxo).
- Doxo has been shown to increase markers of senescence in human endothelial cells, linked to the activation of the NLRP3 inflammasome and the release of interleukin-1β.
- Resolvins, specifically resolvin E1 (RvE1), may help mitigate Doxo-induced endothelial senescence by inhibiting key inflammatory pathways, suggesting new therapeutic possibilities for reducing cardiovascular toxicity from Doxo.